Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
THTX 
Theratechnologies Inc. (THTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/02/2025: THTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.04
1 Year Target Price $4.04
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.61% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 155.87M USD | Price to earnings Ratio - | 1Y Target Price 4.04 |
Price to earnings Ratio - | 1Y Target Price 4.04 | ||
Volume (30-day avg) 3 | Beta 0.81 | 52 Weeks Range 1.12 - 3.40 | Updated Date 10/21/2025 |
52 Weeks Range 1.12 - 3.40 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.85% | Operating Margin (TTM) -10.74% |
Management Effectiveness
Return on Assets (TTM) 7.33% | Return on Equity (TTM) -1116.86% |
Valuation
Trailing PE - | Forward PE 55.87 | Enterprise Value 181131265 | Price to Sales(TTM) 1.85 |
Enterprise Value 181131265 | Price to Sales(TTM) 1.85 | ||
Enterprise Value to Revenue 2.15 | Enterprise Value to EBITDA 74.63 | Shares Outstanding 45980019 | Shares Floating 38229167 |
Shares Outstanding 45980019 | Shares Floating 38229167 | ||
Percent Insiders 1.15 | Percent Institutions 45.49 |
Upturn AI SWOT
Theratechnologies Inc.
Company Overview
History and Background
Theratechnologies Inc. is a specialty pharmaceutical company addressing unmet medical needs. Founded in 1993, it initially focused on HIV-related complications and has since expanded to oncology. Significant milestones include the approval of Egrifta and Trogarzo.
Core Business Areas
- HIV: Focuses on treatments for HIV patients experiencing metabolic complications. Includes Trogarzo (ibalizumab-uiyk) for multidrug-resistant HIV-1 infection.
- Oncology: Focuses on treatments for cancer patients. Includes Tesamorelin, a growth hormone-releasing factor analogue currently in clinical trials for NASH and cancer-related indications.
Leadership and Structure
The leadership team includes Paul Lu00e9vesque (President and CEO) and other executives in finance, R&D, and commercial operations. The company has a typical corporate structure with a Board of Directors overseeing management.
Top Products and Market Share
Key Offerings
- Trogarzo: Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor. It is indicated, in combination with other antiretrovirals, for the treatment of adults with multidrug-resistant HIV-1 infection who are failing their current antiretroviral regimen. While specific market share data fluctuates, it competes with other antiretroviral therapies. Competitors include Gilead Sciences, ViiV Healthcare, and Merck.
- Egrifta/Egrifta SV: Egrifta and Egrifta SV (tesamorelin) are growth hormone-releasing factor analogs indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. Competitors include generic growth hormone therapies and lifestyle modifications.
Market Dynamics
Industry Overview
The specialty pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and strong competition. Focus is on niche markets with unmet needs.
Positioning
Theratechnologies occupies a niche position focusing on HIV and oncology supportive care. Its competitive advantage lies in its specialized products and expertise in these areas.
Total Addressable Market (TAM)
The TAM for HIV and oncology supportive care is substantial, estimated in billions of dollars. Theratechnologies is positioned to capture a share of this market through its specialized products. TAM size is difficult to define precisely but it encompasses all those with HIV and cancers that would benefit from the medicines Theratechnologies markets or is developing.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Established presence in niche markets
- Experienced management team
- Proprietary technologies
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Dependence on regulatory approvals
- Relatively small market capitalization
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and acquisitions
- Development of innovative therapies
- Geographic expansion
Threats
- Competition from larger pharmaceutical companies
- Patent expiration
- Changes in healthcare regulations
- Generic entry
Competitors and Market Share
Key Competitors
- GILD
- MRK
- VTRS
Competitive Landscape
Theratechnologies competes with larger pharmaceutical companies. It has an advantage in specialized products but faces disadvantages in terms of resources and market reach.
Growth Trajectory and Initiatives
Historical Growth: Theratechnologies' historical growth has been driven by sales of Egrifta and Trogarzo. Growth rates have fluctuated depending on market conditions and competition.
Future Projections: Future growth projections depend on analyst estimates and company guidance, focusing on new product launches and market expansion.
Recent Initiatives: Recent initiatives include clinical trials for new indications and strategic partnerships to expand market reach.
Summary
Theratechnologies is a niche pharmaceutical company focused on HIV and oncology. Its strengths lie in its specialized product portfolio, but weaknesses include reliance on limited products and smaller scale. Opportunities exist in expanding therapeutic areas, while threats include competition and regulatory changes. Overall, the company needs to leverage its expertise to drive growth and mitigate risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change, impacting future results. Accuracy of market share data not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theratechnologies Inc.
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2016-01-04 | President, CEO & Director Mr. Paul Lévesque | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.theratech.com |
Full time employees - | Website https://www.theratech.com | ||
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin F8 in HIV-associated lipodystrophy that is in Phase 2 clinical trials for the treatment of nonalcoholic steatohepatitis; SORT1+ Technology that is in Phase 1 clinical trials for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; sudocetaxel zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company also commercializes olezarsen, an RNA-targeted medicine for the treatment of familial chylomicronemia syndrome and severe hypertriglyceridemia; and donidalorsen, an RNA-targeted medicine that targets the acute attacks of hereditary angioedema. The company was incorporated in 1993 and is headquartered in Montreal, Canada. As of September 25, 2025, Theratechnologies Inc. operates as a subsidiary of CB Biotechnology, LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.